| Corticosteroids (prednisone ± prednisolone) |
Severe alcoholic hepatitis (Model for End-Stage Liver Disease, MELD ≥ 15 or Lille score < 0.45 at day 7) |
Randomized trials (e.g., the 2010 JAMA study) showed reduced 6‑month mortality in steroid responders. |
Requires careful monitoring for infections, GI bleed risk; not for mild disease. |
| N‑acetylcysteine (NAC) |
Early alcoholic hepatitis, particularly with co‑existing acetaminophen toxicity |
Meta‑analyses show improved short‑term survival when given early. |
Can be given IV (for acute) or orally; inexpensive. |
| Pentoxifylline |
Alcoholic hepatitis (non‑steroid responders) |
Small trials suggest decreased hepatic encephalopathy; benefit is modest. |
Oral dosing; watch for GI upset. |
| Ursodeoxycholic acid (UDCA) |
Mild cholestasis in ARLD |
Some observational data suggest modest benefit in fibrosis progression; not universally endorsed. |
Oral; monitor for pruritus. |
| Vitamin A, E, B12, folate |
General nutritional support |
Correcting deficiencies can improve liver function tests. |
Not a standalone therapy, but essential in malnourished patients. |
| Antioxidants & anti‑fibrotic agents |
Experimental (e.g., silymarin, silybin, obeticholic acid) |
Limited high‑quality evidence; still under investigation. |
Use with caution; talk to hepatology. |
| Sofosbuvir / ledipasvir |
Not used for ARLD – for viral hepatitis |
— |
— |